
|Articles|September 1, 2003
Infliximab Tx Effects Dramatic in Psoriasis and Psoriatic Arthritis
Chicago - Results of two multicenter, double-blind, placebo-controlled trials support the conclusion that the TNF-a chimeric monoclonal antibody infliximab (Remicade) is a highly effective and generally well-tolerated treatment for psoriasis and psoriatic arthritis, Alan D. Menter, M.D., said.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
AbbVie Files for Vitiligo Indication, Putting Systemic Therapy Under Regulatory Review
2
Icotrokinra Shows Superior Efficacy Over Advanced Oral Therapies in New Psoriasis Meta-Analysis
3
Nutrafol Expands Portfolio with First and Only Hair Loss Supplement for Male Patients 50 and Older
4
Introducing Dermatology Times NP/PA Connect
5











